WALTHAM, Mass., Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023.
Read more at prnewswire.comAeglea BioTherapeutics Announces Reverse Stock Split
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
